2498-50-2 Usage
Description
4-Aminobenzamidine dihydrochloride is a synthetic diamidine derivative characterized by its white to yellowish fine crystalline powder appearance. It possesses significant chemical properties and is recognized for its ability to act as a urokinase inhibitor as well as a trypsin inhibitor, making it a versatile compound in various scientific and medical applications.
Uses
Used in Pharmaceutical and Biochemical Research:
4-Aminobenzamidine dihydrochloride is used as a ligand in affinity chromatography for the purification and immobilization of enzymes. Its ability to inhibit certain enzymes makes it a valuable tool in the study and manipulation of enzymatic processes.
Used in Synthesis of Orally Active Drugs:
In the pharmaceutical industry, 4-Aminobenzamidine dihydrochloride is utilized in the synthesis of orally active fibrinogen receptor antagonists based on benzamidines. These antagonists are crucial in the development of treatments for conditions related to blood clotting and vascular health.
Used in Development of Selective Serine Protease Inhibitors:
The compound is also employed in the creation of benzamidine derivatives that serve as selective and potent serine protease inhibitors. These inhibitors have applications in the treatment of various diseases and disorders where serine proteases play a significant role.
Used in the Synthesis of Novel Anticancer Agents:
4-Aminobenzamidine dihydrochloride is used in the synthesis of novel pyrrolo[3,2-c]quinolines, which are structural analogs of topoisomerase inhibitors such as coralyne and fagaronine. These analogs hold potential in the development of new anticancer drugs.
Used in the Synthesis of Enzyme Inhibitors:
Additionally, 4-Aminobenzamidine dihydrochloride is involved in the synthesis of a selective inhibitor of PRMT1 (SKLB-639), which is an important target for the development of therapies against various diseases, including cancer.
Preparation
4-Aminobenzamididine dihydrochloride is obtained by cyanation, addition, amination and reduction of 4-nitrobenzoic acid.
Check Digit Verification of cas no
The CAS Registry Mumber 2498-50-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,4,9 and 8 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2498-50:
(6*2)+(5*4)+(4*9)+(3*8)+(2*5)+(1*0)=102
102 % 10 = 2
So 2498-50-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H9N3/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H3,9,10)/p+1
2498-50-2Relevant articles and documents
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform
Pant, Shishir M.,Mukonoweshuro, Amanda,Desai, Bimbisar,Ramjee, Manoj K.,Selway, Christopher N.,Tarver, Gary J.,Wright, Adrian G.,Birchall, Kristian,Chapman, Timothy M.,Tervonen, Topi A.,Klefstr?m, Juha
supporting information, p. 4335 - 4347 (2018/05/14)
Hepsin is a membrane-anchored serine protease whose role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis. Using an integrated design, synthesis, and screening platform, we were able to rapidly develop potent and selective inhibitors of hepsin. In progressing from the initial hit 7 to compound 53, the IC50 value against hepsin was improved from ~1 μM to 22 nM, and the selectivity over urokinase-type plasminogen activator (uPA) was increased from 30-fold to >6000-fold. Subsequent in vitro ADMET profiling and cellular studies confirmed that the leading compounds are useful tools for interrogating the role of hepsin in breast tumorigenesis.
Design, synthesis and structure-activity relationships of novel diaryl urea derivatives as potential EGFR inhibitors
Jiang, Nan,Bu, Yanxin,Wang, Yu,Nie, Minhua,Zhang, Dajun,Zhai, Xin
, (2016/12/03)
Two novel series of diaryl urea derivatives 5a-i and 13a-l were synthesized and evaluated for their cytotoxicity against H-460, HT-29, A549, and MDA-MB-231 cancer cell lines in vitro. Therein, 4-aminoquinazolinyl-diaryl urea derivatives 5a-i demonstrated significant activity, and seven of them are more active than sorafenib, with IC50 values ranging from 0.089 to 5.46 μM. Especially, compound 5a exhibited the most active potency both in cellular (IC50 = 0.15, 0.089, 0.36, and 0.75 μM, respectively) and enzymatic assay (IC50 = 56 nM against EGFR), representing a promising lead for further optimization.
PROCESS FOR THE MANUFACTURE OF 4-AMINOBENZOAMIDINE DIHYDROCHLORIDE
-
Page/Page column 10-11, (2014/05/24)
The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I), preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.